ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garrett, H. E.
Right arrow Articles by Suggs, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garrett, H. E., Jr
Right arrow Articles by Suggs, R.
Related Collections
Right arrow Transplantation - heart

Ann Thorac Surg 2002;74:1240-1242
© 2002 The Society of Thoracic Surgeons

Case report

Treatment of humoral rejection with rituximab

H. Edward Garrett, Jr, MD*a,b, Kenneth Groshart, MDa,b, Denise Duvall-Seaman, RN, BSNa,b, Deena Combs, RN, BSNa,b, Rita Suggs, RN, BSNa,b

a Division of Cardiothoracic Surgery, University of Tennessee, Memphis, Tennessee, USA
b Baptist Hospital/University of Tennessee Heart Transplant Program, Memphis, Tennessee, USA

Accepted for publication May 1, 2002.

* Address reprint requests to Dr Garrett, 80 Humphreys Blvd, Suite 300, Memphis, TN 38120 USA

Humoral vascular rejection is a B cell-mediated production of immunoglobulin G antibody against the transplanted organ. Available treatments of vascular rejection offer limited success, and chronic manifestations of vascular rejection require retransplantation. On the basis of the mechanism of action of rituximab, we successfully treated 1 patient with vascular rejection refractory to plasmapheresis with this drug without major toxicity.




This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
D E Furst, E C Keystone, B Kirkham, R Fleischmann, P Mease, F C Breedveld, J S Smolen, J R Kalden, G R Burmester, J Braun, et al.
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008
Ann Rheum Dis, December 1, 2008; 67(Suppl_3): iii2 - iii25.
[Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
N. Z. Sulemanjee, R. Merla, S. D. Lick, S. M. Aunon, M. Taylor, M. Manson, L. S.C. Czer, and E. R. Schwarz
The First Year Post-Heart Transplantation: Use of Immunosuppressive Drugs and Early Complications
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2008; 13(1): 13 - 31.
[Abstract] [PDF]

Home page
 Card Surg AdultHome page
B. P. Griffith, M. Haddad, and R. S. Poston
Immunobiology of Heart and Heart-Lung Transplantation
Card. Surg. Adult, January 1, 2008; 3(2008): 1513 - 1538.
[Full Text]

Home page
 Journal of Pharmacy PracticeHome page
L. M. McDevitt
Immunosuppressive Agents on the Horizon
Journal of Pharmacy Practice, December 1, 2003; 16(6): 434 - 441.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2002 by The Society of Thoracic Surgeons.